Overview

Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide

Status:
Recruiting
Trial end date:
2022-02-21
Target enrollment:
Participant gender:
Summary
This is a Phase 1, 2-period, multiple-dose, open-label, single fixed sequence study of the effect of ritlecitinib on tolbutamide pharmacokinetics in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Tolbutamide